Jefferies lowered the firm’s price target on Alnylam (ALNY) to $549 from $550 and keeps a Buy rating on the shares. The firm notes Q3 sales were strong, driven by rapid Amvuttra uptake for CM. Management commented “broad” access and uptake across tx naive and stabilizer progressors in academic plus community centers and with an expanded prescriber base. Jefferies further points out that Alnylam increased 2025 TTR revenue guidance substantially. For pipeline, obesity, CNS, and bleeding disorders data expected in 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma: Strong Sales Growth and Financial Performance Justify Buy Rating
- Alnylam reports Q3 EPS $1.84, consensus $1.75
- ALNY Upcoming Earnings Report: What to Expect?
- Alnylam Pharmaceuticals: Strong Market Performance and Promising Pipeline Drive Buy Rating
- Alnylam’s ZENITH Study: A New Horizon in Cardiovascular Treatment